Molecure SA
WSE:MOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Molecure SA
Operating Expenses
Molecure SA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Molecure SA
WSE:MOC
|
Operating Expenses
-zł20.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
C
|
Celon Pharma SA
WSE:CLN
|
Operating Expenses
-zł249.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabis Poland SA
WSE:CBD
|
Operating Expenses
-zł2.5m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
See Also
What is Molecure SA's Operating Expenses?
Operating Expenses
-20.8m
PLN
Based on the financial report for Dec 31, 2025, Molecure SA's Operating Expenses amounts to -20.8m PLN.
What is Molecure SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-10%
Over the last year, the Operating Expenses growth was 31%. The average annual Operating Expenses growth rates for Molecure SA have been -6% over the past three years , -10% over the past five years .
